More than 200 Spanish professionals, to which must be added a large group of Latin American specialists who will follow the online forum, will participate during the next three days in Salamanca in the XIV Symposium on Biological Bases and Therapeutic Innovation, organized to delve into the latest advances in cancer research and its application to new therapies to combat cancer in its many aspects.
The symposium, founded almost 23 years ago, under different names, by Dr. Juan Jesús Cruz, a renowned specialist who until last year was head of the Medical Oncology Service at the University Hospital of Salamanca, has been based since its inception on «deepen in the knowledge of the biology of tumors to achieve a more precise diagnosis and treatment».
In this sense, as explained by Dr. Cruz, one of the main barriers faced in the sector is "guaranteeing the sustainability of a system in which it is possible to incorporate therapeutic innovation in an agile and equitable manner". As he has clarified, "equity implies that a patient cannot and should not be treated differently depending on his place of residence." An issue on which he adds that "this does not mean that all resources have to be available in all places, but that all patients have access to them through their health systems in the appropriate centers." "This is one of the main challenges that must be faced both in clinical practice and in cancer research," he added.
Also participating in the scientific coordination of the symposium is Dr. Emilio Fonseca, current Head of the Medical Oncology Service at Salamanca Hospital, who points out the importance of "precision medicine" in this field. A "priority" focus on the service he leads. Fonseca has valued the "normalization" that the return of the symposium brings to its face-to-face celebration after two years of doing it electronically due to the pandemic, which "is fine", but according to nuance, "they do not allow that more intimate contact between doctors and researchers.